SCHEMBL4611286

SCHEMBL4611286

O=CN[C@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.54
NAALAD2 Q9Y3Q0 1/20 0.54
SLC7A5 Q01650 1/20 0.51
MME P08473 5/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ACE P12821 7/20 0.49
CPA1 P15085 1/20 0.49
ACE2 Q9BYF1 1/20 0.49
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3799467 1.00 FOLH1 (0.54) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL2703294 1.00 FOLH1 (0.54) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL10494110 0.98 FOLH1 (0.52) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL10494109 0.98 FOLH1 (0.52) FOLH1NAALAD2SLC7A5MMEMEN1
Trifluoroacetic Acid SCHEMBL29695528 0.92 ACE (0.53) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL10537166 0.91 FOLH1 (0.47) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL9052244 0.86 FOLH1 (0.43) FOLH1NAALAD2SLC7A5MMEMEN1
SCHEMBL697901 0.86 EPHX1 (0.61) FOLH1NAALAD2MMEMEN1KMT2A
SCHEMBL697900 0.86 EPHX1 (0.61) FOLH1NAALAD2MMEMEN1KMT2A
SCHEMBL8211678 0.86 EPHX1 (0.61) FOLH1NAALAD2MMEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105523964-B Preparation method of anti-heart-failure drug intermediate 苏州楚凯药业有限公司 2017-05-24 CN claimed
CN-105523964-A Preparation method of anti-heart-failure drug intermediate SUZHOU CHUKAI PHARMATECH CO LTD 2016-04-27 CN claimed
EP-1621546-B1 Peptide ligands specific to immonoglobulins TECNOGEN SPA (IT) 2008-10-29 EP claimed
EP-1621546-A1 Peptide ligands specific to immonoglobulins TECNOGEN S.C.P.A. (IT) 2006-02-01 EP claimed
CN-105523964-B Preparation method of anti-heart-failure drug intermediate 苏州楚凯药业有限公司 2017-05-24 CN disclosed
CN-105523964-B Preparation method of anti-heart-failure drug intermediate 苏州楚凯药业有限公司 2017-05-24 CN disclosed
CN-105523964-A Preparation method of anti-heart-failure drug intermediate SUZHOU CHUKAI PHARMATECH CO LTD 2016-04-27 CN disclosed
CN-105523964-A Preparation method of anti-heart-failure drug intermediate SUZHOU CHUKAI PHARMATECH CO LTD 2016-04-27 CN disclosed
CN-102352392-B Chemical-enzyme method for preparing D-tyrosine UNIV CHONGQING POSTS & TELECOM 2013-11-06 CN disclosed
CN-102352392-A Chemical-enzyme method for preparing D-tyrosine UNIV CHONGQING POSTS & TELECOM 2012-02-15 CN disclosed
EP-1621546-B1 Peptide ligands specific to immonoglobulins TECNOGEN SPA (IT) 2008-10-29 EP disclosed
EP-1621546-A1 Peptide ligands specific to immonoglobulins TECNOGEN S.C.P.A. (IT) 2006-02-01 EP disclosed
CN-1235871-C Process for preparing D-tyrosine UNIV NINGBO TECHNOLOGY (CN) 2006-01-11 CN disclosed
CN-1569818-A Process for preparing D-tyrosine UNIV NINGBO TECHNOLOGY (CN) 2005-01-26 CN disclosed